Stockreport

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024 [Yahoo! Finance]

Aurinia Pharmaceuticals Inc - Common Shares  (AUPH) 
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.auriniapharma.com
PDF Additional data on baseline demographics from the Enlight-LN registry and safety and efficacy data of LUPKYNIS will also be presented. ROCKVILLE, Md. & EDMONTON, Albe [Read more]